- Home
- SNBR vs ALT Comparison
SNBR vs ALT Comparison
Compare SNBR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- ALT
- Stock Information
- Founded
- SNBR 1987
- ALT 1997
- Country
- SNBR United States
- ALT United States
- Employees
- SNBR N/A
- ALT N/A
- Industry
- SNBR Home Furnishings
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- SNBR Consumer Discretionary
- ALT Health Care
- Exchange
- SNBR Nasdaq
- ALT Nasdaq
- Market Cap
- SNBR 399.8M
- ALT 472.3M
- IPO Year
- SNBR 1998
- ALT N/A
- Fundamental
- Price
- SNBR $7.63
- ALT $5.80
- Analyst Decision
- SNBR Hold
- ALT Strong Buy
- Analyst Count
- SNBR 2
- ALT 7
- Target Price
- SNBR $9.00
- ALT $21.00
- AVG Volume (30 Days)
- SNBR 785.0K
- ALT 2.0M
- Earning Date
- SNBR 04-30-2025
- ALT 05-13-2025
- Dividend Yield
- SNBR N/A
- ALT N/A
- EPS Growth
- SNBR N/A
- ALT N/A
- EPS
- SNBR N/A
- ALT N/A
- Revenue
- SNBR $1,605,108,000.00
- ALT $20,000.00
- Revenue This Year
- SNBR N/A
- ALT N/A
- Revenue Next Year
- SNBR $4.19
- ALT N/A
- P/E Ratio
- SNBR N/A
- ALT N/A
- Revenue Growth
- SNBR N/A
- ALT N/A
- 52 Week Low
- SNBR $4.48
- ALT $3.55
- 52 Week High
- SNBR $20.75
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- SNBR 57.34
- ALT 60.47
- Support Level
- SNBR $6.63
- ALT $4.95
- Resistance Level
- SNBR $8.61
- ALT $6.05
- Average True Range (ATR)
- SNBR 0.63
- ALT 0.37
- MACD
- SNBR 0.23
- ALT 0.11
- Stochastic Oscillator
- SNBR 72.47
- ALT 85.17
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.